Dydrogesterone/Estradiol

地屈孕酮/雌二醇

Report date: 2024/08/21 10:38:49

Base Information

Drug NameDydrogesterone/Estradiol
Drug Alias NameEstradiol/Dydrogesterone雌二醇/地屈孕酮FemostonClimastonFemoston-Conti
ClassificationSmall molecules > Steroids
Mechanisms of ActionEstrogen receptors agonistsProgesterone receptor agonists
TargetsEstrogen receptorsProgesterone receptor
Therapy Area/IndicationsOestrogen deficiency symptomsMenopausal symptomsEndocrine System Diseases +[5] 
Global Approved IndicationsOestrogen deficiency symptomsMenopausal symptomsOsteoporosis, Postmenopausal
Approved Indications in ChinaOestrogen deficiency symptomsMenopausal symptoms
Original Approved Country/TerritoryNetherlands
Original Approved Date1997/05/05
Country/TerritoryNetherlandsMainland China
CombinationsYes EstradiolDydrogesterone
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAbbott Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesAbbott LaboratoriesAbbott Bv
Inactive CompaniesAbbott Biologicals BVAbbott Healthcare Products BvSohag University +[5] 
Active IndicationsOestrogen deficiency symptomsMenopausal symptomsOsteoporosis, Postmenopausal
Inactive IndicationsEndocrine System DiseasesPolycystic Ovary Syndrome

Other Information

ATC CodeG03FA
Related LinksN/A